U
TRIB

UBS’s Trinity Biotech TRIB Stock Holding History

UBS’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$216K Sell
79
-3
-4% -$9.75K ﹤0.01% 5107
2014
Q2 		$284K Buy
82
+54
+193% +$192K ﹤0.01% 4807
2014
Q1 		$101K Sell
28
-4
-13% -$15.7K ﹤0.01% 5965
2013
Q4 		$119K Sell
32
-8
-20% -$28.8K ﹤0.01% 5870
2013
Q3 		$131K Sell
40
-9
-18% -$26.3K ﹤0.01% 5705
2013
Q2 		$123K Buy
+49
New +$122K ﹤0.01% 5655

Other funds holding TRIB

HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
AAM
ACK Asset Management Greenwich, Connecticut $801M AUM 60.42% 1-Year Est. Return
LSC
Lyon Street Capital Sausalito, California $67M AUM
WA
Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.85% 1-Year Est. Return
TAM
THB Asset Management Norwalk, Connecticut $440M AUM 59.59% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
CAM
Cortina Asset Management Milwaukee, Wisconsin $1.62B AUM 15.44% 1-Year Est. Return

UBS's TRIB Position: Q3 2014 in Review

UBS reduced its Trinity Biotech (TRIB) stake by 3.7% in Q3 2014, selling an estimated $9.75K and leaving 79 shares worth $216K. The position accounts for ﹤0.01% of the portfolio, ranked #5107.

UBS first reported a position in TRIB in Q2 2013 and has held it in 6 quarters since. The position peaked at $284K in Q2 2014. 93 funds tracked by Wall St. Rank hold TRIB as of Q3 2014.

  • UBS held 79 shares of Trinity Biotech worth $216K as of Q3 2014.
  • UBS sold 3 Trinity Biotech shares in Q3 2014, an estimated $9.75K.
  • Trinity Biotech made up ﹤0.01% of UBS's portfolio in Q3 2014, its #5107 holding.
  • UBS first reported a position in Trinity Biotech in Q2 2013 and has held it in 6 quarters since.
  • UBS's Trinity Biotech position peaked at $284K in Q2 2014.
  • 93 funds tracked by Wall St. Rank held Trinity Biotech as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.